Neuland Laboratories

Neuland Laboratories commenced operations at the first of four commercial peptide manufacturing modules at its peptide site on 15 September 2026. The module offered 7,000 litres of total reactor capacity, including 750 litres of solid-phase synthesis and 6,250 litres of liquid-phase synthesis in separate suites for parallel operation, supported by three chromatography columns, two lyophilisers and a team of nearly 212 peptide specialists following a $30 million investment. Foundational infrastructure for a second module of up to 18,000 litres was already in place, with configuration and capacity being defined with an anchor customer and partner interest broadening from obesity and metabolic disease into oncology. The start-up completed the first leg of a four-module peptide programme that sat alongside additional commercial capacities commissioned at Unit 1 and Unit 3 in July 2026, within an approved capital programme of about ₹1,460 crore of which about ₹870 crore had been spent. Neuland reported gross revenue of about ₹2,053 crore in FY26 with custom manufacturing services accounting for over half the mix, and total income of ₹650.1 crore in the June quarter at an EBITDA margin of 35.5%.

Powered by Tijori

Sept 7 (Reuters) - Neuland Laboratories Limited NEUL.NS:

• APPROVES CAPITAL EXPENDITURE OF 1.26 BILLION RUPEES FOR LAND PURCHASE IN KAKINADA

Further company coverage: NEUL.NS

(([email protected];))

Aug 14 (Reuters) - Neuland Laboratories Ltd NEUL.NS:

• US FDA INSPECTS NEULAND LABORATORIES UNIT 3 FROM AUGUST 10 TO 14, 2026

• US FDA ISSUES FORM 483 WITH ONE OBSERVATION AFTER INSPECTION

Source text:

Further company coverage: NEUL.NS

(([email protected];))

Aug 5 (Reuters) - Neuland Laboratories Ltd NEUL.NS:

• NEULAND LABORATORIES JUNE-QUARTER CONSOL PROFIT 1.48 BILLION RUPEES

• NEULAND LABORATORIES JUNE-QUARTER CONSOL REVENUE FROM OPERATIONS 6.42 BILLION RUPEES

• NEULAND LABORATORIES LTD - TO ADD MANUFACTURING CAPACITY AT UNIT-1, BONTHAPALLY VILLAGE FOR 398 BILLION RUPEES

Source text: ID:nBSE905rVX

Further company coverage: NEUL.NS

(([email protected];))

May 12 (Reuters) - Neuland Laboratories Ltd NEUL.NS:

• NEULAND LABORATORIES LTD MARCH-QUARTER CONSOL PROFIT 2.13 BILLION RUPEES

• NEULAND LABORATORIES LTD MARCH-QUARTER CONSOL REVENUE FROM OPERATIONS 7.76 BILLION RUPEES

• NEULAND LABORATORIES LTD DECLARES DIVIDEND OF 34 RUPEESPER SHARE

Source text: ID:nBSE9Q6xDJ

Further company coverage: NEUL.NS

(([email protected];;))

April 1 (Reuters) - Neuland Laboratories Ltd NEUL.NS:

• APPOINTS SAHARSH DAVULURI AS CEO AND MANAGING DIRECTOR

Source text: ID:nBSE2R5705

Further company coverage: NEUL.NS

(([email protected];))

Feb 9 (Reuters) - Neuland Laboratories Ltd NEUL.NS:

• NEULAND LABORATORIES DEC-QUARTER CONSOL PROFIT 405.7 MILLION RUPEES

• NEULAND LABORATORIES LTD DEC-QUARTER CONSOL REVENUE FROM OPERATIONS 4.4 BILLION RUPEES

Source text: ID:nBSE2gtQPh

Further company coverage: NEUL.NS

(([email protected];))

Nov 28 (Reuters) - Neuland Laboratories Ltd NEUL.NS:

• NEULAND LABORATORIES LTD - APPROVES 1.89 BILLION RUPEES FOR NEW RESEARCH AND DEVELOPMENT CENTER

Source text: ID:nBSE4hb3vV

Further company coverage: NEUL.NS

(([email protected];))

** Shares of Neuland Laboratories NEUL.NS fall 3.2% to 12,854 rupees

** Drug manufacturer posts nearly 86% Y/Y decline in June-qtr consol profit; rev from ops drops about 57%

** Trading volume at nearly 190,976 shares so far, about 1.6x 30-day avg

** Stock down 6.3% YTD

(Reporting by Rudra Pratap Singh in Bengaluru)

(([email protected]))

June 17 (Reuters) - Neuland Laboratories Ltd NEUL.NS:

• NEULAND LABORATORIES - SEBI ISSUES ADMINISTRATIVE WARNING FOR INSIDER TRADING VIOLATION

Source text: ID:nNSE2btbtK

Further company coverage: NEUL.NS

(([email protected];))

** India's Neuland Laboratories NEUL.NS down 6.04% at 13,782 rupees after Q3 results

** Stock set for worst day since Nov. 6 when it reported Q2 results

** Bulk drug manufacturer's Q3 core profit declines by 26.4% y/y, while revenue increases less than 2%

** Stock has more than doubled in value in the last 12 months

(Reporting by Ananta Agarwal in Bengaluru)

(([email protected]))

** Neuland Laboratories NEUL.NS rises 4% to 13,751 rupees; set for biggest one-day gain in more than two weeks

** Drug maker approves capital expenditure of 3.42 billion rupees ($39.5 million) to increase co's peptide synthesizer reactor capacity from 0.5 KL to 6.37 KL

** Stock sees busiest day in a week, with more than 33,000 shares traded

** NEUL surged 159% in 2024 vs a 23% gain in peer Aurobindo Pharma ARBN.NS

($1 = 86.5690 Indian rupees)

(Reporting by Aleef Jahan in Bengaluru)

(([email protected]))

Jan 21 (Reuters) - Neuland Laboratories Ltd NEUL.NS:

• NEULAND LABORATORIES LTD - APPROVED CAPITAL EXPENDITURE OF 3.42 BILLION RUPEES

Source text: ID:nBSE1z0h6l

Further company coverage: NEUL.NS

(([email protected];))

Dec 13 (Reuters) - Neuland Laboratories Ltd NEUL.NS:

• TRANSFERRED FINAL PART OF PROPERTY VIA LEASE FOR 234.5 MILLION RUPEES

Source text: ID:nBSE5V3ygz

Further company coverage: NEUL.NS

(([email protected];;))

** Shares of pharmaceutical firm Neuland Laboratories NEUL.NS slip 5% to 16,070 rupees

** An undisclosed vendor has launched 7.5 billion rupees block share sale at floor price of 15,428 rupees, a 9% discount to prev. close, IFR reports

** Media reports say Smallcap World Fund is the likely seller

** Smallcap World Fund holds 3.8% stake in NEUL, per exchange data

** More than 800,000 shares of NEUL changed hands in most-active session since May 2023

** Stock has tripled in 2024

(Reporting by Nishit Navin)

(([email protected];))

Nov 6 (Reuters) - Neuland Laboratories Ltd NEUL.NS:

• SEPT-QUARTER CONSOL PROFIT 328.4 MILLION RUPEES

• SEPT-QUARTER CONSOL REVENUE FROM OPERATIONS 3.11 BILLION RUPEES

Source text: ID:nBSE35Fb6F

Further company coverage: NEUL.NS

(([email protected];;))

Aug 1 (Reuters) - Neuland Laboratories Ltd NEUL.NS:

• NEULAND LABORATORIES - CAPEX OF ABOUT 245 MILLION RUPEES FOR ENHANCING CAPACITY AT UNIT

• NEULAND LABORATORIES LTD JUNE-QUARTER CONSOL PROFIT 978.7 MILLION RUPEES

• NEULAND LABORATORIES LTD JUNE-QUARTER CONSOL REVENUE FROM OPERATIONS 4.4 BILLION RUPEES

Source text for Eikon: [ID:]

Further company coverage: NEUL.NS

(([email protected];))

** Shares of Neuland Laboratories NEUL.NS down as much as 14.7% to 6,088.10 rupees, their biggest intraday pct loss since March 2020

** Pharmaceutical firm on Friday reported a 20% Y/Y fall in its March-qtr consolidated profit to 675.6 mln rupees ($8.1 mln)

** Revenue from operations fell 5.4% Y/Y

** EBITDA margin contracts to 28.7% from 30.8% a year earlier

** More than 80,000 shares change hands by 10:23 a.m. IST, 2.4x their 30-day avg volume

** Stock on track for a third straight session of losses, if trend holds

** Including session's move, stock is up 16.2% YTD

($1 = 83.5150 Indian rupees)

(Reporting by Navamya Ganesh Acharya in Bengaluru)

(([email protected]; +91 8805175330 ;))

May 10 (Reuters) - Neuland Laboratories Ltd NEUL.NS:

• NEULAND LABORATORIES LTD- WILL CONTINUE TO INVEST FOR FUTURE BY ADDING CAPACITY AND CAPABILITIES

Source text for Eikon: ID:nBSE39yLSC

Further company coverage: NEUL.NS

(([email protected];))

** Shares of contract research firm Syngene International SYNN.NS up 2.1% and pharmaceuticals firm Neuland Laboratories NEUL.NS up 4.8%

** Goldman Sachs initiates stocks with a 'buy' rating, sets street-high PTs of 875 rupees for SYNN and 9,100 rupees for NEUL; highlights improving funding for biotech, capacity ramp-up and new contract wins

** Brokerage believes India's share in global contract research/drug manufacturing will rise as companies reduce dependence on China; lists SYNN, NEUL as its top picks in sector

** "Any progress" on U.S. bill that prohibits federal agencies from contracting with China biotech companies/service providers, "could bring in disproportionate benefits" to NEUL - Goldman

** Meanwhile, shares of Laurus Labs LAUL.NS down 1.7% after brokerage initiates stock with "sell"

** NEUL up 23.5% so far this year, vastly outperforming LAUL's 5% rise and SYNN's 8.9% growth

(Reporting by Nandan Mandayam in Bengaluru)

(([email protected]; Mobile: +91 9591011727;))

** Shares of pharmaceutical firm Neuland Laboratories NEUL.NS rise as much as 6.8% to 6,463.95 rupees

** Co says U.S. Food and Drug Administration completed inspection at its Hyderabad facility with zero observations

** NEUL last up 5.7%, set for highest weekly gains in March if trend holds

** NEUL trading above 50-, 100- day simple moving averages

(Reporting by Anisha Ajith in Bengaluru)

(([email protected]))

Feb 8 (Reuters) - Neuland Laboratories Ltd NEUL.NS:

• NEULAND LABORATORIES DEC-QUARTER CONSOL PROFIT 813.9 MILLION RUPEES VERSUS PROFIT 305.5 MILLION RUPEES

• NEULAND LABORATORIES DEC-QUARTER CONSOL REVENUE FROM OPERATIONS 3.93 BILLION RUPEES VERSUS 2.69 BILLION RUPEES

Source text for Eikon: ID:nBSE7FC8NP

Further company coverage: NEUL.NS

(([email protected];))

** Shares of Neuland Laboratories NEUL.NS fall 2% to 5,060 rupees

** Davuluri Rama Mohan Rao, a large shareholder in the co, sold 400,000 shares amounting to 3.12% stake through open market transactions, NEUL said post market hours on Friday

** Rao held 24.71% stake in NEUL at the end of September quarter, according to National Stock Exchange data

** Trading volume is 95,424 shares as of 2:44 p.m. IST, 1.7 times the 30-day avg - LSEG data

** Including day's losses so far, stock still up 204% in 2023

(Reporting by Bharath Rajeswaran in Bengaluru)

(([email protected]; +91 9769003463;))

Dec 8 (Reuters) - Neuland Laboratories Ltd NEUL.NS:

• NEULAND LABORATORIES LTD- DAVULURI RAMA MOHAN RAO, PROMOTER, SOLD 3.12 % STAKE THROUGH OPEN MARKET

• NEULAND LABORATORIES LTD- SALE AT AVERAGE PRICE OF 5,012.45 RUPEES PER SHARE

• NEULAND LABORATORIES LTD- DAVULURI FAMILY DOES NOT PLAN TO SELL ANY FURTHER SHARES IN FORESEEABLE FUTURE

Source text for Eikon: ID:nNSE2y2hwY

Further company coverage: NEUL.NS

(([email protected];))

Nov 10 (Reuters) - Neuland Laboratories Ltd NEUL.NS:

• APPROVED CAPITAL EXPENDITURE OF 1.28 BILLION RUPEES FOR ENHANCING CAPACITY AT UNIT 3

Source text for Eikon: ID:nNSE9P1x1y

Further company coverage: NEUL.NS

(([email protected];))

** Shares of Indian active pharma ingredients (API) maker Neuland Labs NEUL.NS rise as much as 8.2% to a record high of 4,994 rupees

** Co on Tuesday reported Q2 profit that more than doubled, while margins rose 820 basis points from a year ago

** Profit was driven by focus on high margin custom manufacturing solutions business (CMS), co said

** CMS business caters to exclusive customers, developing and manufacturing APIs and intermediates

** About 152,000 shares change hands, ~ 5x 30-day avg as of 12:34 p.m. IST

** NEUL shares have nearly tripled so far this year

(Reporting by Sethuraman NR in Bengaluru)

(([email protected]; (+91 8061822737); Reuters Messaging: [email protected]))

Nov 7 (Reuters) - Neuland Laboratories Ltd NEUL.NS:

• INDIA'S NEULAND LABORATORIES SEPT-QUARTER CONSOL PROFIT 892.5 MILLION RUPEES VERSUS PROFIT 384.6 MILLION RUPEES

• NEULAND LABORATORIES LTD SEPT-QUARTER CONSOL REVENUE FROM OPERATIONS 4.18 BILLION RUPEES VERSUS 2.94 BILLION RUPEES

Source text for Eikon: ID:nBSE7c81vZ

Further company coverage: NEUL.NS

(([email protected];;))